347 related articles for article (PubMed ID: 31108259)
1. Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy.
Qiu Q; Li C; Song Y; Shi T; Luo X; Zhang H; Hu L; Yan X; Zheng H; Liu M; Liu M; Liu M; Yang S; Liu X; Chen G; Deng Y
Acta Biomater; 2019 Jul; 92():184-195. PubMed ID: 31108259
[TBL] [Abstract][Full Text] [Related]
2. Targeting Ibrutinib to Tumor-Infiltrating T Cells with a Sialic Acid Conjugate-Modified Phospholipid Complex for Improved Tumor Immunotherapy.
Li C; Fan C; Lu S; Qiu Q; Gao X; Yan X; Wang S; Zhao B; Liu X; Song Y; Deng Y
Mol Pharm; 2023 Jan; 20(1):438-450. PubMed ID: 36382950
[TBL] [Abstract][Full Text] [Related]
3. Terminating the renewal of tumor-associated macrophages: A sialic acid-based targeted delivery strategy for cancer immunotherapy.
Ding J; Zhao D; Hu Y; Liu M; Liao X; Zhao B; Liu X; Deng Y; Song Y
Int J Pharm; 2019 Nov; 571():118706. PubMed ID: 31593811
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity.
Zhou S; Zhang T; Peng B; Luo X; Liu X; Hu L; Liu Y; Di D; Song Y; Deng Y
Int J Pharm; 2017 May; 523(1):203-216. PubMed ID: 28336455
[TBL] [Abstract][Full Text] [Related]
5. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
Yang M; Li J; Gu P; Fan X
Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of zoledronic acid through the sialic acid - Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages - A promising cancer immunotherapy.
Tang X; Sui D; Liu M; Zhang H; Liu M; Wang S; Zhao D; Sun W; Liu M; Luo X; Lai X; Liu X; Deng Y; Song Y
Int J Pharm; 2020 Nov; 590():119929. PubMed ID: 33010395
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacodynamics of liposomes modified with different chain length of sialic acid derivatives].
Song YZ; Huang ZJ; Luo X; Wang MJ; Zheng JH; Shi J; Deng YH
Yao Xue Xue Bao; 2016 Feb; 51(2):316-24. PubMed ID: 29856587
[TBL] [Abstract][Full Text] [Related]
8. NIR-Actuated Targeted Janus Nanomotors Remodel Immunosuppressive Tumor Microenvironment for Augmented Cancer Immunotherapy.
Zhou X; Ma E; Zhang Y; Xing Y; Xu W; Chen L; Zhou H; Zhang X; Jiang C; Xu K; Wang H; Zheng S
Adv Healthc Mater; 2024 Jan; 13(2):e2302272. PubMed ID: 37824087
[TBL] [Abstract][Full Text] [Related]
9. Sialic acid-decorated liposomes enhance the anti-cancer efficacy of docetaxel in tumor-associated macrophages.
Tran NP; Tran P; Yoo SY; Tangchang W; Lee S; Lee JY; Son HY; Park JS
Biomater Adv; 2023 Nov; 154():213606. PubMed ID: 37678087
[TBL] [Abstract][Full Text] [Related]
10. Sialic-Acid-Anchored Micelles: A Hierarchical Targeting Device for Enhanced Tumor Tissue Accumulation and Cellular Internalization.
Zhu ML; Xu XL; Wang XJ; Zhang NN; Lu KJ; Qi J; Jin FY; Liu D; Du YZ
Mol Pharm; 2018 Sep; 15(9):4235-4246. PubMed ID: 30110551
[TBL] [Abstract][Full Text] [Related]
11. Novel Self-Assembled Ibrutinib-Phospholipid Complex for Potently Peroral Delivery of Poorly Soluble Drugs with pH-Dependent Solubility.
Qiu Q; Lu M; Li C; Luo X; Liu X; Hu L; Liu M; Zheng H; Zhang H; Liu M; Lai C; Song Y; Deng Y
AAPS PharmSciTech; 2018 Nov; 19(8):3571-3583. PubMed ID: 30209789
[TBL] [Abstract][Full Text] [Related]
12. The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.
Ping L; Ding N; Shi Y; Feng L; Li J; Liu Y; Lin Y; Shi C; Wang X; Pan Z; Song Y; Zhu J
Oncotarget; 2017 Jun; 8(24):39218-39229. PubMed ID: 28424405
[TBL] [Abstract][Full Text] [Related]
13. Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes.
Wei L; Su YK; Lin CM; Chao TY; Huang SP; Huynh TT; Jan HJ; Whang-Peng J; Chiou JF; Wu AT; Hsiao M
Oncotarget; 2016 Oct; 7(43):69961-69975. PubMed ID: 27564106
[TBL] [Abstract][Full Text] [Related]
14. Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.
Stiff A; Trikha P; Wesolowski R; Kendra K; Hsu V; Uppati S; McMichael E; Duggan M; Campbell A; Keller K; Landi I; Zhong Y; Dubovsky J; Howard JH; Yu L; Harrington B; Old M; Reiff S; Mace T; Tridandapani S; Muthusamy N; Caligiuri MA; Byrd JC; Carson WE
Cancer Res; 2016 Apr; 76(8):2125-36. PubMed ID: 26880800
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic/ photothermal therapy enhances neutrophil-mediated ibrutinib tumor delivery for potent tumor immunotherapy: More than one plus one?
Qiu Q; Li C; Yan X; Zhang H; Luo X; Gao X; Liu X; Song Y; Deng Y
Biomaterials; 2021 Feb; 269():120652. PubMed ID: 33450581
[TBL] [Abstract][Full Text] [Related]
16. Sialic acid conjugate-modified liposomes enable tumor homing of epirubicin via neutrophil/monocyte infiltration for tumor therapy.
Ding J; Sui D; Liu M; Su Y; Wang Y; Liu M; Luo X; Liu X; Deng Y; Song Y
Acta Biomater; 2021 Oct; 134():702-715. PubMed ID: 34339869
[TBL] [Abstract][Full Text] [Related]
17. An Application of Tumor-Associated Macrophages as Immunotherapy Targets: Sialic Acid-Modified EPI-Loaded Liposomes Inhibit Breast Cancer Metastasis.
Meng X; Wang M; Zhang K; Sui D; Chen M; Xu Z; Guo T; Liu X; Deng Y; Song Y
AAPS PharmSciTech; 2022 Oct; 23(8):285. PubMed ID: 36258152
[TBL] [Abstract][Full Text] [Related]
18. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Song Y; Tang C; Yin C
Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
[TBL] [Abstract][Full Text] [Related]
19. Targeted depletion of tumour-associated macrophages by an alendronate-glucomannan conjugate for cancer immunotherapy.
Zhan X; Jia L; Niu Y; Qi H; Chen X; Zhang Q; Zhang J; Wang Y; Dong L; Wang C
Biomaterials; 2014 Dec; 35(38):10046-57. PubMed ID: 25245263
[TBL] [Abstract][Full Text] [Related]
20. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
